Rezdiffra (Resmetirom) Pediatric (Under 12) Dosing

The Short Answer: Resmetirom Is Not Approved for Children Under 12

Rezdiffra has no approved pediatric dose for patients under 12. Period. The FDA approval issued on March 14, 2024 covers adults only, and the prescribing information carries no weight-based or age-based dosing table for children. Clinicians treating young children with MASH should not prescribe resmetirom off-label given the complete absence of pharmacokinetic, safety, or efficacy data in this age group.

Why the Gap Exists

The MAESTRO-NASH trial, the key study supporting FDA approval, enrolled 966 adults aged 18 and older [1]. No pediatric cohort was included. Madrigal Pharmaceuticals designed the program around adult noncirrhotic MASH with biopsy-confirmed fibrosis stage F2 or F3, the population carrying the highest unmet need at the time the drug entered development.

Pediatric MASH, while clinically real and growing in prevalence, presents distinct histological patterns compared to adult disease. A 2023 analysis published in Hepatology noted that pediatric NAFLD/MASH often shows zone 3 sparing with periportal rather than centrilobular injury, a pattern that may respond differently to THR-beta agonism [2]. That biological difference, combined with the absence of any trial data, makes extrapolation from adult dosing tables scientifically indefensible for children under 12.

What the FDA Requires Going Forward

Under the Pediatric Research Equity Act (PREA), the FDA can require manufacturers of newly approved drugs to submit a Pediatric Study Plan (PSP) when a drug treats a disease that occurs in children [3]. The FDA's March 2024 approval letter for resmetirom included a deferred pediatric study requirement, meaning Madrigal Pharmaceuticals must conduct and submit pediatric studies, though the timeline for completion extends beyond the initial approval date. The specific deferral conditions and timelines are published in the FDA approval package [4].

Adult Dosing of Resmetirom: The Only Approved Regimen

Understanding the adult dosing framework matters for context, particularly for clinicians who may eventually extrapolate to adolescents as data emerge. The approved adult doses are 80 mg once daily (for adults with body weight <100 kg) and 100 mg once daily (for adults with body weight 100 kg or more), taken orally with or without food [4].

The MAESTRO-NASH Trial Results

MAESTRO-NASH (N=966) was a phase 3, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2024 [1]. At 52 weeks, the co-primary endpoints were NASH resolution without worsening fibrosis and fibrosis improvement by at least one stage without worsening NASH activity.

Results were statistically significant on both endpoints. NASH resolution occurred in 25.9% of patients on resmetirom 80 mg and 29.9% on resmetirom 100 mg, compared with 9.7% in the placebo group (P<0.001 for both doses vs. Placebo) [1]. Fibrosis improvement by one or more stages occurred in 24.2% (80 mg) and 25.9% (100 mg) of resmetirom-treated patients, versus 14.2% with placebo (P<0.001) [1].

The FDA cited these findings as sufficient to support accelerated approval for a condition with no previously approved pharmacological therapy.

Drug Interactions and Metabolism Relevant to a Pediatric Future

Resmetirom is primarily metabolized by CYP3A4 and undergoes additional processing via CYP2C8 [4]. In children, CYP3A4 activity per kilogram body weight differs substantially from adults, with higher relative activity in children aged 1 to 10 years that gradually declines toward adult rates [5]. Any future pediatric dose would require dedicated pharmacokinetic modeling to avoid supratherapeutic exposure. That modeling does not yet exist for children under 12.

Pediatric MASH: Prevalence, Diagnosis, and the Clinical Stakes

Metabolic-associated steatohepatitis is not rare in children. Estimates suggest that approximately 10% of obese children in the United States carry MASH, not just simple steatosis [6]. With childhood obesity rates continuing to climb, the downstream burden of pediatric fibrotic liver disease is a genuine public health concern.

How Pediatric MASH Differs Histologically

The 2005 NASH Clinical Research Network classification identified a distinct pediatric pattern (Type 2 NAFLD) characterized by portal-based inflammation and steatosis with minimal lobular injury [7]. Adult MASH typically shows centrilobular ballooning and lobular inflammation (Type 1). This distinction is clinically important because most pharmacological agents, including resmetirom, were developed around the adult histological phenotype.

A drug that selectively activates THR-beta to reduce hepatic lipogenesis and improve mitochondrial fat oxidation addresses pathways relevant to both patterns. But "relevant" and "proven safe and effective in children" are very different claims.

Growth and Thyroid Axis Considerations

Thyroid hormone receptor-beta is expressed predominantly in the liver, but some THR-beta activity occurs in the developing pituitary and hypothalamic-pituitary-thyroid axis. In animal reproductive toxicity studies cited in the Rezdiffra prescribing information, resmetirom caused fetal harm at exposures below the clinical dose [4]. The pediatric thyroid axis in children under 12 is in active maturation. Introducing a THR-beta agonist during this window carries theoretical risks to thyroid feedback regulation that have not been studied in humans of any pediatric age.

This is not a theoretical concern extrapolated from unrelated drugs. The FDA explicitly flagged thyroid-related monitoring requirements in the adult label and listed changes in thyroid function tests as adverse events occurring in clinical trials [4].

Current Standard of Care for MASH in Children Under 12

No drug is FDA-approved for MASH in any pediatric age group. The 2023 American Association for the Study of Liver Diseases (AASLD) guidance on pediatric NAFLD/MASH specifies lifestyle intervention as the foundation of treatment for all children, including those with biopsy-confirmed MASH [8].

Lifestyle Intervention: What the Evidence Actually Shows

The TONIC trial (N=173, ages 8 to 17) compared vitamin E 800 IU/day, metformin 500 mg twice daily, and placebo over 96 weeks in children with NAFLD confirmed by biopsy [9]. Neither active arm met the primary endpoint of sustained reduction in ALT. Vitamin E did improve NASH resolution on biopsy (58% vs. 28% placebo, P=0.006) but did not achieve significant fibrosis improvement [9]. Metformin showed no histological benefit over placebo.

Dietary caloric restriction combined with increased physical activity remains the only intervention with consistent evidence for reducing liver fat in children, though effects on fibrosis are modest and adherence in the under-12 age group is challenging to sustain.

GLP-1 Receptor Agonists in Pediatric MASH

Semaglutide and liraglutide are approved for obesity in adolescents (age 12 and older for semaglutide, age 12 and older for liraglutide), but neither carries an indication for MASH in any pediatric group [10]. Case series and small observational studies suggest GLP-1 receptor agonists may reduce hepatic steatosis in adolescents, but no randomized controlled trial has demonstrated histological MASH resolution or fibrosis regression in children under 12.

What Clinicians Should Document

Any child under 12 presenting with suspected MASH warrants liver biopsy only when noninvasive markers (MRE, FibroScan, serum ELF score) suggest advanced fibrosis or when the diagnosis would change clinical management. Routine screening of all obese children for MASH is endorsed by the American Academy of Pediatrics (AAP) 2023 obesity guidelines via ALT measurement beginning at age 9 to 11 in children with obesity [11].

What Families and Clinicians Should Expect as Resmetirom Pediatric Data Develops

The pathway from adult approval to pediatric availability typically takes 5 to 10 years for hepatic drugs requiring biopsy endpoints, based on the precedent set by drugs like obeticholic acid (which received adult accelerated approval in 2016 for primary biliary cholangitis and did not complete pediatric studies until years later). Resmetirom's pediatric timeline will follow a similar arc.

The Likely Pediatric Study Design

Based on FDA PREA guidance and historical precedent for metabolic liver drugs, a pediatric resmetirom study would most likely proceed in stages. An initial phase 1 pharmacokinetic study would enroll adolescents (12 to 17) first, followed by dose-finding in younger children (6 to 11) if the adolescent PK data support safe exposure. Biopsy-confirmed MASH with fibrosis stage F2 or F3 would be required for enrollment, mirroring the adult MAESTRO-NASH eligibility criteria.

Regulatory precedent suggests that a weight-based dosing scheme would be evaluated at two to three weight bands, rather than a single flat dose. Whether 80 mg and 100 mg remain appropriate anchor doses for adolescents with body weight above 40 to 50 kg is unknown; exposure modeling will drive those decisions.

How to Monitor a Child with MASH While Awaiting Evidence

Children with confirmed MASH and fibrosis should receive follow-up liver stiffness measurement (via MRE or FibroScan) every 12 to 24 months, along with ALT, AST, GGT, and fasting lipid panel. Annual fasting glucose and HbA1c screening is appropriate given the frequent co-occurrence of prediabetes and metabolic syndrome in this population. Body weight, BMI z-score, and blood pressure should be tracked at every visit.

Families should be counseled explicitly that resmetirom is not available to children under 12 and that no off-label use should occur outside of an IRB-approved clinical trial. If a trial opens, enrollment referral to a tertiary NAFLD center (such as those in the NASH Clinical Research Network) gives the child the best access to investigational options.

Resmetirom Safety Profile: Adult Data With Pediatric Implications

The Rezdiffra prescribing information identifies the most common adverse reactions in adults as nausea (26% resmetirom vs. 16% placebo) and diarrhea (28% vs. 16%) [4]. These gastrointestinal effects were predominantly mild to moderate and occurred most frequently in the first 4 to 8 weeks of therapy.

Hepatic Safety Signal

Transient elevations in liver enzymes (ALT or AST greater than three times the upper limit of normal) occurred in approximately 5.6% of resmetirom-treated patients in MAESTRO-NASH [1]. In children with already elevated baseline ALT from MASH, parsing a drug-induced elevation from disease progression would be particularly difficult without established pediatric reference ranges for this compound.

Biliary Effects

Resmetirom increased the lithogenicity of bile in animal studies [4]. Gallstone formation and biliary sludge have been noted as adverse events in adult trials. Pediatric biliary physiology differs from adults in ways that could affect susceptibility, though no data exist to quantify that risk in children under 12.

Reproductive Toxicity

The FDA label carries a clear contraindication in pregnancy, supported by animal studies showing embryofetal harm at exposures below the human clinical dose [4]. While this is less immediately applicable to children under 12, clinicians treating pubertal patients (ages 10 to 12) should factor reproductive potential into any future prescribing decision as pediatric approvals develop.

Regulatory Milestones to Watch

The FDA's Center for Drug Evaluation and Research (CDER) publishes Pediatric Study Plans and deferral status for approved drugs. Clinicians and researchers can track the resmetirom pediatric study requirement through the FDA's publicly accessible pediatric drug development database [3].

Key milestones that would signal progress toward pediatric availability include:

• Publication of an Initial Pediatric Study Plan (iPSP) agreed upon between Madrigal Pharmaceuticals and the FDA
• First-in-pediatric phase 1 PK data in adolescents aged 12 to 17
• Opening of a phase 2/3 trial in children aged 6 to 11 with biopsy-confirmed MASH
• Submission of a supplemental New Drug Application (sNDA) with pediatric data to the FDA

None of these milestones had been publicly announced as of the publication date of this article.